Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network

Table 1

Baseline demographics and disease characteristics by regimen.

	Treatment-experienced, non-ETR; (𝑁= 15,084)^a	All ETR; (𝑁=587)	ETR w/o PI; (𝑛=178)	ETR w/PI not DRV/r; (𝑛=69)	ETR w/DRV/r; (𝑛=340)	ETR w/o PI/RAL; (𝑛=56)	ETR w/PI; w/o RAL; (𝑛=139)	ETR w/RAL w/o PI; (𝑛=122)	ETR w/PI/RAL; (𝑛=270)
Baseline characteristics
Male, 𝑛 (%)	10,667 (70.7)	434 (73.9)	107 (60.1)	47 (68.1)	280 (82.4)	30 (53.6)	107 (77.0)	77 (63.1)	220 (81.5)
Median (range) age at start of ETR regimen, years	44 (18, 90)	47 (18, 86)	48 (22, 86)	45 (18, 63)	46 (21, 79)	46 (22, 78)	46 (18, 79)	49 (24, 86)	46 (21, 72)
Race, 𝑛 (%)
White	3858 (25.6)	144 (24.5)	35 (19.7)	15 (21.7)	94 (27.7)	10 (17.9)	29 (20.9)	25 (20.5)	80 (29.6)
Black	7581(50.3)	291 (49.6)	85 (47.8)	37 (53.6)	169 (49.7)	21 (37.5)	71 (51.1)	64 (52.5)	135 (50.0)
Hispanic	3272 (21.7)	140 (23.9)	53 (29.8)	16 (23.2)	71 (20.9)	23 (41.1)	37 (26.6)	30 (24.6)	50 (18.5)
Other	373 (2.5)	12 (2.0)	5 (2.8)	1 (1.4)	6 (1.8)	2 (3.6)	2 (1.4)	3 (2.5)	5 (1.9)
IDU, 𝑛 (%)	2614 (17.3)	102 (17.4)	36 (20.2)	14 (20.3)	52 (15.3)	13 (23.2)	23 (16.6)	23 (18.9)	43 (15.9)
Median (range) years in care	4 (0, 22)	7 (0, 22)	6 (0, 19)	8 (0, 22)	7 (0, 20)	4.5 (0, 19)	7 (0, 19)	7 (0, 19)	8 (0, 22)
Median (range) CD4+ nadir, cells/mL	170 (0, 1802); 𝑛= 14,334	57 (0, 1260); 𝑛=572	104 (0, 749)	72.5 (0, 594)	55 (0, 1260)	200 (6, 708)	73 (0, 1260)	70.5 (0, 749)	44 (0, 720)
Median (range) baseline CD4+ cell count, cells/mL	322 (0, 3167); 𝑛= 12,059	240 (0, 1187); 𝑛=501	242.5 (2, 1134)	232 (4, 770)	244 (0, 1187)	292 (7, 1031)	258.5 (3, 899)	201 (2, 1134)	228 (0, 1187)
Six-month outcomes
Durability (still on ETR), 𝑛 (%)	NA	526 (89.6)	157 (88.2)	59 (85.5)	310 (91.2)	49 (87.5)	125 (89.9)	108 (88.5)	244 (90.4)
Median (range) change in CD4+ cell count (observed), cells/mL	NA	65 (−483, 570)	76 (−341, 361)	89 (−132, 527)	62 (−483, 570)	103.5 (−123, 361)	24.5 (−157, 276)	49 (−341, 278)	74 (−483, 570)
Suppressed HIV-1 RNA (<400 copies/mL; observed), 𝑛/𝑛 (%)	NA	244/314 (77.7)	65/89 (73.0)	30/37 (81.1)	149/188 (79.3)	13/24 (54.2)	54/70 (77.1)	52/65 (80.0)	125/155 (80.6)
Suppressed HIV-1 RNA (<50 copies/mL; observed), 𝑛/𝑛 (%)	NA	161/314 (51.3)	45/89 (50.6)	13/37 (35.1)	103/188 (54.8)	8/24 (33.3)	38/70 (54.3)	37/65 (56.9)	78/155 (50.3)

aAll treatment-experienced patients from the HIVRN who did not receive ETR; ETR: etravirine; w/o: without; PI: protease inhibitor; w/: with; DRV/r: darunavir and ritonavir; RAL: raltegravir; PI/RAL: protease inhibitor and raltegravir; IDU: injection drug use; NA: not applicable; VL: viral load; HIVRN: HIV Research Network.